达格列净对射血分数减低型心衰患者预后的影响
Effect of Dapagliflozin on Prognosis of Patients with Heart Failure with Reduced Ejection Fraction
摘要: 心力衰竭(简称心衰)是各种心脏疾病的末期表现和最重要的死因，在全球有千万患者，目前对于HFrEF，虽经合理化治疗，其预后并未得到显著的改善，目前，对心衰患者的药物治疗一直处于研究中，达格列净为SGLT-2抑制剂的一种，在用于糖尿病患者的降糖治疗中发现其可以降低心血管不良事件的发生率，随后有研究表明达格列净可显著降低心衰患者的住院率，死亡率、各种复合事件，可以使得心衰患者的预后得到很好地改善，本文就达格列净对心衰患者的获益做一综述。
Abstract: Heart failure (referred to as heart failure) is the final manifestation and the main cause of death of cardiovascular diseases. There are millions of patients in the world. At present, although HFrEF has undergone strict standardized treatment, the survival rate was not obviously improved. At present, the drug treatment for patients with heart failure has been under study. Dapagliflozin belongs to SGLT-2I, which can reduce the incidence of cardiovascular adverse events in hypoglycemic treatment of diabetic patients. After a large study, it was shown that Dapagliflozin can significantly reduce the hospitalization rate of patients with heart failure, and the mortality rate and various complex events can improve the prognosis of patients with heart failure. This article reviews the benefits of Dapagliflozin to patients with heart failure.
文章引用：杨欣, 姚建强. 达格列净对射血分数减低型心衰患者预后的影响[J]. 临床医学进展, 2021, 11(11): 5322-5326. https://doi.org/10.12677/ACM.2021.1111786

参考文献

[1] Bozkurt, B., Coats, A.J.S., Tsutsui, H., et al. (2021) Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, 23.
[2] Orso, F., Fabbri, G. and Maggioni, A.P. (2017) Epidemiology of Heart Failure. In: Handbook of Experimental Pharmacology, Vol. 243, Springer, Berlin, 15-33.
[Google Scholar] [CrossRef] [PubMed]
[3] Bonneux, L., Barendregt, J.J. and Meeter, K. (1994) Estimating Clinical Morbidity Due to Ischemic Heart Disease and Congestive Heart Failure: The Future Rise of Heart Failure. American Journal of Public Health, 84, 20-28.
[Google Scholar] [CrossRef] 
[4] Neumiller, J.J., White, J.R. and Campbell, R.K. (2010) Sodium-Glucose Co-Transport Inhibitors Progress and Therapeutic Potential in Type 2 Diabetes Mellitus. Drugs, 70, 377-385.
[Google Scholar] [CrossRef] [PubMed]
[5] Sunil, N. and Wilding, J.P.H. (2010) Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism, 95, 34-42.
[6] Meng, W., Ellsworth, B.A., Nirschl, A.A., et al. (2008) Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes. Journal of Medicinal Chemistry, 51, 1145-1149.
[Google Scholar] [CrossRef] [PubMed]
[7] McMurray, J.J.V. and Solomon, S.D. (2019) Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 381, 1995-2008.
[8] Kato, E.T., Silverman, M.G., Mosenzon, O., et al. (2019) Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 139, 2528-2536.
[Google Scholar] [CrossRef] 
[9] Kosiborod, M., Gause-Nilsson, I., Xu, J., et al. (2017) Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes and Concomitant Heart Failure. Journal of Diabetes & Its Complications, 31, 1215-1221.
[Google Scholar] [CrossRef] [PubMed]
[10] Petrie, M.C., Verma, S., Docherty, K.F., et al. (2020) Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients with Heart Failure with and without Diabetes. JAMA: The Journal of the American Medical Association, 323, 1353-1368.
[Google Scholar] [CrossRef] [PubMed]
[11] Mcalister, F.A., Ezekowitz, J., Tarantini, L., et al. (2012) Renal Dysfunction in Patients with Heart Failure with Preserved versus Reduced Ejection Fraction: Impact of the New Chronic Kidney Disease-Epidemiology Collaboration Group Formula. Circulation: Heart Failure, 5, 309-314.
[Google Scholar] [CrossRef] 
[12] Jhund, P.S., Solomon, S.D., Docherty, K.F., et al. (2020) Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF. Circulation, 143, 298-309.
[13] Tang, H.L., Li, D.D., et al. (2017) Sodium-Glucose Co-Transporter-2 Inhibitors and Risk of Adverse Renal Outcomes among Patients with Type 2 Diabetes: A Network and Cumulative Meta-Analysis of Randomized Controlled Trials. Diabetes, Obesity and Metabolism, 19, 1106-1115.
[14] Kohan, D.E., Fioretto, P., Tang, W., et al. (2013) Long-Term Study of Patients with Type 2 Diabetes and Moderate Renal Impairment Shows That Dapagliflozin Reduces Weight and Blood Pressure But Does Not Improve Glycemic Control. Kidney International, 85, 962-971.
[Google Scholar] [CrossRef] [PubMed]
[15] Jabbour, S. (2017) Durability of Response to Dapagliflozin: A Review of Long-Term Efficacy and Safety. Current Medical Research & Opinion, 33, 1685-1696.
[Google Scholar] [CrossRef] [PubMed]
[16] Tucker, R., Quinn, J.R., Chen, D.G., et al. (2016) Kansas City Cardiomyopathy Questionnaire Administered to Hospitalized Patients with Heart Failure. Journal of Nursing Measurement, 24, 245-257.
[Google Scholar] [CrossRef] [PubMed]
[17] Green, C.P., Porter, C.B., Bresnahan, D.R., et al. (2000) Development and Evaluation of the Kansas City Cardiomyopathy Questionnaire: A New Health Status Measure for Heart Failure. Journal of the American College of Cardiology, 35, 1245-1255.
[Google Scholar] [CrossRef] 
[18] Nassif, M.E., Windsor, S.L., Tang, F., et al. (2019) Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction. Circulation, 140, 1463-1476.
[Google Scholar] [CrossRef] 
[19] Li, N.J., Guo, L.X., Guo, X.H., et al. (2016) Expert Guidance on Clinical Practice of Sodium Glucose Co-Transporter 2 Inhibitor in China. Chinese Journal of Diabetes.
[20] Wilding, J., Woo, V., Rohwedder, K., et al. (2014) Dapagliflozin in Patients with Type 2 Diabetes Receiving High Doses of Insulin: Efficacy and Safety over 2 Years. Diabetes Obesity & Metabolism, 16, 124-136.
[Google Scholar] [CrossRef] [PubMed]
[21] Wilding, J. (2019) SGLT2 Inhibitors and Urinary Tract Infections. Nature Reviews Endocrinology, 15, 687-688.
[Google Scholar] [CrossRef] [PubMed]

为你推荐